CA-ARCTIC-BLUE-BEVERAGES
12.4.2022 18:02:09 CEST | Business Wire | Press release
Products of the Finnish beverage company Arctic Blue Beverages succeeded nobly at the prestigious The San Francisco World Spirit Competition (SFWSC). The company's newest gins, Arctic Blue Legacy Gin and Arctic Blue Gin Rose, won double gold. Silver was awarded to the innovative oat liqueur, Arctic Blue Oat.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005706/en/
“Although we know our products rank high in taste and quality globally, this was still an overwhelming result, for a relatively small player in the global alcohol industry,” Valtteri Eroma, the CEO of Arctic Blue Beverages, rejoices.
“Developing new products is always a team effort, but the key role in the taste of Arctic Blue products plays our internationally awarded Master Distiller Asko Ryynänen. With Asko, we have developed an agile process to turn ideas effectively into award-winning products, which is now paying off,” Valtteri adds.
Arctic Blue Legacy is a barrel-aged gin sold in a unique bottle designed by Timo Sarpaneva. The product is targeted to the ultra-premium category and packed in a prestige handmade wooden gift package. It has already received the highest recognition at the International Wine and Spirit Competition (IWSC) with a gold medal and 95 points back in 2021.
Arctic Blue Gin Rose is the company's entry into the fast-growing category of pink gins. The taste profile is similar to the multi-award winning Arctic Blue Gin with hints of cinnamon rose petals in both scent and taste. The beautiful red color comes from Finnish bilberries.
Arctic Blue Oat is the world’s first gin-based oat liqueur, which was launched a year ago. It was already awarded with a bronze medal at the International Wine and Spirit Competition (IWSC) in 2021.
“Based on our experience after previous awards, this will give a great boost to the sales of our new products as well as our current products like Arctic Blue Oat. Therefore, immediately after hearing the preliminary information, we have worked hard to increase the production capacity of our products at the distillery,” says Valtteri Eroma.
Products of Arctic Blue Beverages have previously been successful in the SFWSC competition. For example in 2019 Arctic Blue Navy Strength Gin won Double Gold and the Best in Show awards at the World Spirits Awards in San Francisco.
Awards for Arctic Blue Beverages in 2022:
DOUBLE GOLD MEDAL, Arctic Blue Gin Rose (Flavoured Gin Category)
DOUBLE GOLD MEDAL, Arctic Blue Legacy Gin (Barrel Aged Gin Category)
SILVER MEDAL, Arctic Blue Oat, Finland (Other Liqueurs Category)
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005706/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom